The prevalence of GLP-1 drugs for weight loss among U.S. adults has reached a record high, with 11% of the population currently using medications like Ozempic and Wegovy, according to a Gallup survey of 5,065 adults conducted between May 28 and June 5. This surge correlates with a decline in the national obesity rate, which dropped to 36.4% in 2026 from a peak of 39.9% in 2022.
The Shift in Obesity Trends
Data from the Gallup survey conducted between May 28 and June 5 shows that GLP-1 usage has nearly quadrupled in two years. In 2024, only 3% of U.S. adults reported using these drugs for weight loss. When including past usage, the reach extends to 15% of the adult population. As these medications have gained traction, the national obesity rate has experienced a measurable downturn. While the diabetes rate has remained steady, the decrease in obesity is a significant shift following 15 years of consistent increases.
Did you know?
GLP-1 stands for glucagon-like peptide-1. These drugs mimic hormones naturally released by the gut after eating, which helps regulate appetite, digestion, and blood sugar levels.
Brand-Name Drugs vs. Compounded Alternatives
While FDA-approved medications like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound dominate the market, compounded versions—often sold through telehealth providers—remain a point of contention. Gallup found that 10% of users switched from compounded versions to FDA-approved drugs, while one-third of those currently taking compounded GLP-1s transitioned from approved medications.
Affordability is the primary driver for this movement. The survey indicates that individuals who switched to compounded versions were twice as likely to cite insurance coverage or affordability issues as their motivation for the change.
Future Pipelines and Expanded Medical Uses
The landscape for GLP-1 therapy is expanding beyond weight loss. The FDA has already approved Wegovy for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and for reducing cardiovascular risks in adults with obesity and established heart disease. Similarly, Zepbound is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, and Ozempic is used to reduce the risk of worsening chronic kidney disease in adults with type 2 diabetes.
New delivery methods are also entering the market. In December 2025, the FDA cleared a daily pill version of Wegovy, and in April, the agency approved Eli Lilly’s oral weight-loss drug, orforglipron (Foundayo). Researchers are currently exploring further applications for these drugs, including treatments for Alzheimer’s, substance use disorders, and chronic joint pain.
Managing Side Effects and Risks
Despite their clinical success, GLP-1 medications carry potential health risks. Common side effects include nausea, vomiting, diarrhea, and constipation. More severe complications, though rare, include pancreatitis, gallbladder disease, bowel obstruction, stomach paralysis, acute kidney injury, and vision issues. Patients have also reported challenges related to rapid weight loss, such as muscle loss, loose skin, and the return of or emergence of eating disorder symptoms.
Frequently Asked Questions
Are GLP-1 drugs only for diabetes?
No. While initially developed for type 2 diabetes, drugs like Wegovy and Zepbound are FDA-approved for weight loss and have expanded labels for conditions like cardiovascular disease, sleep apnea, and kidney disease.
What is the difference between brand-name and compounded GLP-1s?
Brand-name drugs are FDA-approved. Compounded versions are often sold through telehealth companies and are not FDA-approved, though they are often used by patients due to cost or insurance coverage issues.
What is the next generation of GLP-1 drugs?
The pipeline includes more convenient oral options and more potent injectables. Eli Lilly’s retatrutide, often called “triple G,” mimics three different hormones and is expected to seek FDA approval this year, with early data suggesting higher weight-loss efficacy.
Are you interested in how medical breakthroughs are changing public health? Subscribe to our weekly newsletter for the latest updates on pharmaceutical trends and health policy.
Worth a look